Moderna’s New 9 Dose mRNA Skin Cancer Vaccine Boosts Survival Rates in Melanoma Patients

“If we are able to teach the T-cells of a cancer patient to recognize the mutation of that specific cancer that it could not recognize before, that's a massive medical step forward”

From Moderna’s press release:
“Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone.

Serious treatment-related adverse events occurred in 14.4% of patients who received the combination arm of mRNA-4157/V940 and KEYTRUDA versus 10% with KEYTRUDA alone.”